iRhythm Holdings, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
114.66
-3.65 (-3.09%)
May 13, 2026, 4:00 PM EDT - Market closed
iRhythm Holdings Revenue
iRhythm Holdings had revenue of $199.39M in the quarter ending March 31, 2026, with 25.66% growth. This brings the company's revenue in the last twelve months to $787.85M, up 27.36% year-over-year. In the year 2025, iRhythm Holdings had annual revenue of $747.14M with 26.24% growth.
Revenue (ttm)
$787.85M
Revenue Growth
+27.36%
P/S Ratio
4.78
Revenue / Employee
$328,271
Employees
2,400
Market Cap
3.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 747.14M | 155.30M | 26.24% |
| Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
| Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
| Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
| Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
| Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
| Dec 31, 2019 | 214.55M | 67.28M | 45.68% |
| Dec 31, 2018 | 147.28M | 48.15M | 48.57% |
| Dec 31, 2017 | 99.13M | 35.06M | 54.72% |
| Dec 31, 2016 | 64.07M | 27.93M | 77.29% |
| Dec 31, 2015 | 36.14M | 14.39M | 66.17% |
| Dec 31, 2014 | 21.75M | 6.38M | 41.52% |
| Dec 31, 2013 | 15.37M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.46B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
| Integer Holdings | 1.86B |
| LivaNova | 1.43B |
| Haemonetics | 1.33B |
| Neogen | 870.56M |
| NovoCure | 674.41M |
IRTC News
- 13 hours ago - iRhythm Holdings Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 9 days ago - iRhythm price target raised to $157 from $155 at Citi - TheFly
- 12 days ago - iRhythm price target raised to $174 from $170 at Truist - TheFly
- 12 days ago - iRhythm price target raised to $175 from $166 at Baird - TheFly
- 12 days ago - iRhythm price target lowered to $175 from $215 at JPMorgan - TheFly
- 12 days ago - iRhythm price target lowered to $185 from $225 at Oppenheimer - TheFly
- 12 days ago - iRhythm price target lowered to $160 from $170 at Evercore ISI - TheFly
- 12 days ago - iRhythm price target raised to $255 from $254 at Needham - TheFly